1. Figure 2 Host immune responses, not the radiosensitivity
of cancer cells, correlate with efficacy of radiation therapy (RT)
Figure 2 | Host immune responses, not the radiosensitivity of cancer cells, correlate with efficacy of radiation therapy (RT). We investigated the four possible types of tumour response to radiotherapy using a TUBO (HER2-positive breast cancer) mouse model system164. Tumour cells had similar levels of sensitivity to radiation, despite differential early tumour responses to RT in vivo. Non-RT control, EE (early escape), and R (responsive) tumours were removed for analysis 8 days after RT (or sham treatment); late relapsed and stable tumours were removed for analysis at 21 days post RT. After harvesting, TUBO tumours were digested using collagenase and DNase to generate cell suspensions. The cells were then treated ex vivo with 0, 2, or 5 Gy radiation and were cultured for 7 days, and an in vitro clonogenic assay was performed. The data from the clonogenic assays are displayed as the fraction of cells surviving after radiation treatment, compared with number of colonies formed by the non-irradiated control cells from each type of tumour.
Weichselbaum, R. R. et al. (2017) Radiotherapy and immunotherapy: a beneficial liaison?
Nat. Rev. Clin. Oncol. doi: /nrclinonc